<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36152104</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1661-4917</ISSN><JournalIssue CitedMedium="Internet"><Volume>70</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>24</Day></PubDate></JournalIssue><Title>Archivum immunologiae et therapiae experimentalis</Title><ISOAbbreviation>Arch Immunol Ther Exp (Warsz)</ISOAbbreviation></Journal><ArticleTitle>Angiotensin II Type 1 Receptor Antibodies Are Higher in Lupus Nephritis and Vasculitis than Other Glomerulonephritis Patients.</ArticleTitle><Pagination><StartPage>23</StartPage><MedlinePgn>23</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">23</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00005-022-00660-x</ELocationID><Abstract><AbstractText>Angiotensin II type 1 receptor (AT1R) antibodies are considered non-HLA (human leukocyte antigen) antibodies connected with humoral rejection after kidney transplantation. The role of AT1R antibodies in the pathogenesis of glomerular diseases and systemic vasculitis is unknown. We assessed the level of AT1R antibodies in 136 patients with different types of glomerulonephritis and systemic vasculitis and we observed kidney function and proteinuria, serum albumin and total protein levels for 2&#xa0;years. The mean levels of AT1R antibodies were the following: 6.00&#x2009;&#xb1;&#x2009;1.31&#xa0;U/ml in patients with membranous nephropathy (n&#x2009;=&#x2009;18), 5.67&#x2009;&#xb1;&#x2009;1.31&#xa0;U/ml with focal and segmental glomerulosclerosis (n&#x2009;=&#x2009;25), 6.26&#x2009;&#xb1;&#x2009;2.25&#xa0;U/ml with lupus nephropathy (n&#x2009;=&#x2009;17), 10.60&#x2009;&#xb1;&#x2009;6.72&#xa0;U/ml with IgA nephropathy (n&#x2009;=&#x2009;14), 6.69&#x2009;&#xb1;&#x2009;2.52&#xa0;U/ml with mesangial proliferative (non IgA) glomerulonephritis (n&#x2009;=&#x2009;6), 6.63&#x2009;&#xb1;&#x2009;1.38&#xa0;U/ml with systemic vasculitis (n&#x2009;=&#x2009;56), including c-ANCA (anti-neutrophil cytoplasmic antibodies) vasculitis: 11.22&#x2009;&#xb1;&#x2009;10.78&#xa0;U/ml (n&#x2009;=&#x2009;40) and p-ANCA vasculitis: 12.65&#x2009;&#xb1;&#x2009;14.59&#xa0;U/ml (n&#x2009;=&#x2009;16). The mean AT1R antibodies level was higher in patients with lupus nephropathy and systemic vasculitis compared to glomerulonephritis groups. An inverse statistically significant correlation between AT1R antibodies and serum albumin (r&#x2009;=&#x2009;&#x2009;-&#x2009;0.51) in membranous nephropathy group was also found. Prospective analysis of creatinine levels indicated an increase of creatinine levels during time among patients with higher AT1R antibodies levels in p-ANCA vasculitis. Lupus nephropathy and systemic vasculitis patients may have high levels of AT1R antibodies. AT1R antibodies may be associated with the severity of membranous nephropathy and the course of p-ANCA vasculitis, although influence of concomitant factors is difficult to exclude.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Szymczak</LastName><ForeName>Maciej</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1248-081X</Identifier><AffiliationInfo><Affiliation>Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland. maciej.szymczak@umw.edu.pl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heidecke</LastName><ForeName>Harald</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>CellTrend Gmbh, Luckenwalde, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#x17b;abi&#x144;ska</LastName><ForeName>Marcelina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rukasz</LastName><ForeName>Dagna</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wi&#x15b;nicki</LastName><ForeName>Krzysztof</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tukiendorf</LastName><ForeName>Andrzej</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Social Medicine, Wroclaw Medical University, Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krajewska</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banasik</LastName><ForeName>Miros&#x142;aw</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Grant for Young Investigators nr STM. C160.20.080.</GrantID><Agency>Uniwersytet Medyczny im. Piast&#xf3;w Slaskich we Wroclawiu</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Arch Immunol Ther Exp (Warsz)</MedlineTA><NlmUniqueID>0114365</NlmUniqueID><ISSNLinking>0004-069X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019268">Antibodies, Antineutrophil Cytoplasmic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006680">HLA Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044140">Receptor, Angiotensin, Type 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012709">Serum Albumin</NameOfSubstance></Chemical><Chemical><RegistryNumber>AYI8EX34EU</RegistryNumber><NameOfSubstance UI="D003404">Creatinine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019268" MajorTopicYN="N">Antibodies, Antineutrophil Cytoplasmic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003404" MajorTopicYN="N">Creatinine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005921" MajorTopicYN="Y">Glomerulonephritis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005922" MajorTopicYN="Y">Glomerulonephritis, IGA</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015433" MajorTopicYN="Y">Glomerulonephritis, Membranous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006680" MajorTopicYN="N">HLA Antigens</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044140" MajorTopicYN="N">Receptor, Angiotensin, Type 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012709" MajorTopicYN="N">Serum Albumin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056647" MajorTopicYN="Y">Systemic Vasculitis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014657" MajorTopicYN="Y">Vasculitis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Angiotensin II type 1 receptor antibodies</Keyword><Keyword MajorTopicYN="N">Glomerulonephritis</Keyword><Keyword MajorTopicYN="N">Lupus nephritis</Keyword><Keyword MajorTopicYN="N">Vasculitis</Keyword></KeywordList><CoiStatement>All authors declare no conflict of interest. Blood analysis was performed by CELLTREND (Luckenwalde, Germany) free of charge. Maciej Szymczak, Marcelina &#x17b;abi&#x144;ska, Dagna Rukasz, Krzysztof Grubizna, Magdalena Krajewska, Miros&#x142;aw Banasik have nothing to disclose. Harald Heidecke is CEO and stakeholder of Celltrend GmbH.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>11</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36152104</ArticleId><ArticleId IdType="pmc">PMC9509301</ArticleId><ArticleId IdType="doi">10.1007/s00005-022-00660-x</ArticleId><ArticleId IdType="pii">10.1007/s00005-022-00660-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abuzeineh M, Aala A, Alasfar S, et al. Angiotensin II receptor 1 antibodies associate with post-transplant focal segmental glomerulosclerosis and proteinuria. BMC Nephrol. 2020;21:253. doi: 10.1186/s12882-020-01910-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12882-020-01910-w</ArticleId><ArticleId IdType="pmc">PMC7331243</ArticleId><ArticleId IdType="pubmed">32615995</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajdinovic B, Dragovic T, Magic Z, et al. The importance of angiotensin II type 1 receptor gene polymorphism to losartan treatment in improving glomerulopathy in type 1 diabetic patients. Hell J Nucl Med. 2015;18(Suppl 1):153.</Citation><ArticleIdList><ArticleId IdType="pubmed">26665236</ArticleId></ArticleIdList></Reference><Reference><Citation>Akaishi T, Abe M, Okuda H, et al. High glucose level and angiotensin II type 1 receptor stimulation synergistically amplify oxidative stress in renal mesangial cells. Sci Rep. 2019;9:5214. doi: 10.1038/s41598-019-41536-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-41536-z</ArticleId><ArticleId IdType="pmc">PMC6435641</ArticleId><ArticleId IdType="pubmed">30914692</ArticleId></ArticleIdList></Reference><Reference><Citation>Banasik M, Boraty&#x144;ska M, Ko&#x15b;cielska-Kasprzak K, et al. The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes. Transpl Int. 2014;27:1029&#x2013;1038. doi: 10.1111/tri.12371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tri.12371</ArticleId><ArticleId IdType="pubmed">24909812</ArticleId></ArticleIdList></Reference><Reference><Citation>Banasik M, Boraty&#x144;ska M, Ko&#x15b;cielska-Kasprzak K, et al. Non-HLA antibodies angiotensin II type 1 receptor (anti-AT1R) and endothelin-1 type A receptor (anti-ETAR) are associated with renal allograft injury and graft loss. Transplant Proc. 2014;46:2618&#x2013;2621. doi: 10.1016/j.transproceed.2014.09.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transproceed.2014.09.029</ArticleId><ArticleId IdType="pubmed">25380879</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck LH, Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361:11&#x2013;21. doi: 10.1056/NEJMoa0810457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0810457</ArticleId><ArticleId IdType="pmc">PMC2762083</ArticleId><ArticleId IdType="pubmed">19571279</ArticleId></ArticleIdList></Reference><Reference><Citation>Chertin B, Rolle U, Cascio S, et al. Upregulation of angiotensin II receptors in reflux nephropathy. J Pediatr Surg. 2002;37:251&#x2013;255. doi: 10.1053/jpsu.2002.30266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/jpsu.2002.30266</ArticleId><ArticleId IdType="pubmed">11819209</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow BSM, Kocan M, Shen M, et al. AT1R-AT2R-RXFP1 functional crosstalk in myofibroblasts: Impact on the therapeutic targeting of renal and cardiac fibrosis. J Am Soc Nephrol. 2019;30:2191&#x2013;2207. doi: 10.1681/ASN.2019060597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2019060597</ArticleId><ArticleId IdType="pmc">PMC6830801</ArticleId><ArticleId IdType="pubmed">31511361</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimitrijevic I, Malmsj&#xf6; M, Andersson C, et al. Increased angiotensin II type 1 receptor expression in temporal arteries from patients with giant cell arteritis. Ophthalmology. 2009;116:990&#x2013;996. doi: 10.1016/j.ophtha.2008.12.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2008.12.021</ArticleId><ArticleId IdType="pubmed">19410957</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimitrijevic I, Rissler P, Luts L, et al. Reduced expression of angiotensin II and angiotensin receptor type 1 and type 2 in resistance arteries from nasal lesions in granulomatosis with polyangiitis (Wegener&#x2019;s granulomatosis) Scand J Rheumatol. 2011;40:448&#x2013;452. doi: 10.3109/03009742.2011.593545.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/03009742.2011.593545</ArticleId><ArticleId IdType="pubmed">21936613</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragun D, M&#xfc;ller DN, Br&#xe4;sen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med. 2005;352:558&#x2013;569. doi: 10.1056/NEJMoa035717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa035717</ArticleId><ArticleId IdType="pubmed">15703421</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujita Y, Ichikawa D, Sugaya T, et al. Angiotensin II type 1a receptor loss ameliorates chronic tubulointerstitial damage after renal ischemia reperfusion. Sci Rep. 2021;11:982. doi: 10.1038/s41598-020-80209-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-80209-0</ArticleId><ArticleId IdType="pmc">PMC7806698</ArticleId><ArticleId IdType="pubmed">33441837</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi W, Obata Y, Nishino T, et al. Glomerular repair retardation via blocking of angiotensin II type 1a receptor pathway in a mouse glomerulonephritis model. Nephron Exp Nephrol. 2012;122:13&#x2013;22. doi: 10.1159/000346954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000346954</ArticleId><ArticleId IdType="pubmed">23446008</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue K, Tian X, Velazquez H, et al. Inhibition of endocytosis of clathrin mediated angiotensin II receptor Type 1 in podocytes augments glomerular injury. J Am Soc Nephrol. 2019;30:2307&#x2013;2320. doi: 10.1681/ASN.2019010053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2019010053</ArticleId><ArticleId IdType="pmc">PMC6900791</ArticleId><ArticleId IdType="pubmed">31511362</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinoshita Y, Kondo S, Urushihara M, et al. Angiotensin II type I receptor blockade suppresses glomerular renin-angiotensin system activation, oxidative stress, and progressive glomerular injury in rat anti-glomerular basement membrane glomerulonephritis. Transl Res. 2011;158:235&#x2013;248. doi: 10.1016/j.trsl.2011.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2011.05.003</ArticleId><ArticleId IdType="pubmed">21925120</ArticleId></ArticleIdList></Reference><Reference><Citation>Koffler D, Schur PH, Kunkel HG. Immunological studies concerning the nephritis of systemic lupus erythematosus. J Exp Med. 1967;126:607&#x2013;624. doi: 10.1084/jem.126.4.607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.126.4.607</ArticleId><ArticleId IdType="pmc">PMC2138388</ArticleId><ArticleId IdType="pubmed">4168098</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YT, Chiu HC, Huang CT, et al. The A1166C polymorphism of angiotensin II Type 1 receptor as a predictor of renal function decline over 4 years follow-up in an apparently healthy Chinese population. Clin Nephrol. 2009;72:457&#x2013;467. doi: 10.5414/CNP72457.</Citation><ArticleIdList><ArticleId IdType="doi">10.5414/CNP72457</ArticleId><ArticleId IdType="pubmed">19954723</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefaucher C, Viglietti D, Bouatou Y, et al. Non-HLA agonistic anti-angiotensin II type receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients. Kidney Int. 2019;96:189&#x2013;201. doi: 10.1016/j.kint.2019.01.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2019.01.030</ArticleId><ArticleId IdType="pubmed">31005275</ArticleId></ArticleIdList></Reference><Reference><Citation>Leisman DE, Fernandes TD, Bijol V, et al. Impaired angiotensin II type 1 receptor signaling contributes to sepsis-induced acute kidney injury. Kidney Int. 2021;99:148&#x2013;160. doi: 10.1016/j.kint.2020.07.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2020.07.047</ArticleId><ArticleId IdType="pmc">PMC8030124</ArticleId><ArticleId IdType="pubmed">32882263</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejia-Vilet JM, Lopez-Hernandez YJ, Santander-Velez JI, et al. Angiotensin II receptor agonist antibodies are associated with microvascular damage in lupus nephritis. Lupus. 2020;29:371&#x2013;378. doi: 10.1177/0961203320904787.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320904787</ArticleId><ArticleId IdType="pubmed">32041505</ArticleId></ArticleIdList></Reference><Reference><Citation>Moldoveanu Z, Wyatt RJ, Lee JY, et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int. 2007;71:1148&#x2013;1154. doi: 10.1038/sj.ki.5002185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ki.5002185</ArticleId><ArticleId IdType="pubmed">17342176</ArticleId></ArticleIdList></Reference><Reference><Citation>Philogene MC, Han D, Alvarado F, et al. Prevalence of angiotensin II Type 1 receptor antibodies in persons with hypernsion and relation to blood pressure and medication. Am J Hypertens. 2020;33:734&#x2013;740. doi: 10.1093/ajh/hpaa071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajh/hpaa071</ArticleId><ArticleId IdType="pmc">PMC7530461</ArticleId><ArticleId IdType="pubmed">32330222</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabbadin C, Ceccato F, Ragazzi E, et al. Evaluation of angiotensin II type-1 receptor antibodies in primary aldosteronism and further considerations about their possible pathogenetic role. J Clin Hypertens. 2018;20:1313&#x2013;1318. doi: 10.1111/jch.13351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jch.13351</ArticleId><ArticleId IdType="pmc">PMC8031284</ArticleId><ArticleId IdType="pubmed">30058103</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrankl J, Fuchs M, Broeker K, et al. Localization of angiotensin II Type 1 receptor gene expression in rodent and human kidneys. Am J Physiol Renal Physiol. 2021;320:F644&#x2013;F653. doi: 10.1152/ajprenal.00550.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajprenal.00550.2020</ArticleId><ArticleId IdType="pubmed">33615887</ArticleId></ArticleIdList></Reference><Reference><Citation>Shillitoe EJ, Lehner T, Lessof MH, et al. Letter: Immunological features of Wegener&#x2019;s granulomatosis. Lancet. 1974;1:929. doi: 10.1016/S0140-6736(74)90377-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(74)90377-8</ArticleId><ArticleId IdType="pubmed">4133446</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorohan BM, Ismail G, Leca N, et al. Angiotensin II type 1 receptor antibodies in kidney transplantation: An evidence-based comprehensive review. Transplant Rev. 2020;34:100573. doi: 10.1016/j.trre.2020.100573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trre.2020.100573</ArticleId><ArticleId IdType="pubmed">33002671</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki H, Yamamoto T, Ikegaya N, et al. Dietary salt intake modulates progression of antithymocyte serum nephritis through alteration of glomerular angiotensin II receptor expression. Am J Physiol Renal Physiol. 2004;286:F267&#x2013;277. doi: 10.1152/ajprenal.00059.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajprenal.00059.2003</ArticleId><ArticleId IdType="pubmed">14559715</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki K, Han GD, Miyauchi N, et al. Angiotensin II type 1 and type 2 receptors play opposite roles in regulating the barrier function of kidney glomerular capillary wall. Am J Pathol. 2007;170:1841&#x2013;1853. doi: 10.2353/ajpath.2007.060484.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2007.060484</ArticleId><ArticleId IdType="pmc">PMC1899458</ArticleId><ArticleId IdType="pubmed">17525253</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi M, Rebellato LM, Cai J, et al. Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies. Am J Transplant. 2012;13:2577&#x2013;2589. doi: 10.1111/ajt.12395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.12395</ArticleId><ArticleId IdType="pubmed">23941128</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen Y, Rudemiller NP, Zhang J, et al. Stimulating Type 1 angiotensin receptors on T lymphocytes attenuates renal fibrosis. Am J Pathol. 2019;189:981&#x2013;988. doi: 10.1016/j.ajpath.2019.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2019.02.004</ArticleId><ArticleId IdType="pmc">PMC6521889</ArticleId><ArticleId IdType="pubmed">31000207</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong J, Liang Y, Yang H, et al. The role of angiotensin II type 1 receptor-activating antibodies in patients with lupus nephritis. Int J Clin Pract. 2013;67:1066&#x2013;1067. doi: 10.1111/ijcp.12242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.12242</ArticleId><ArticleId IdType="pubmed">24073980</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu S, Huh HJ, Lee KW, et al. Pre-transplant angiotensin II Type 1 receptor antibodies and anti-endothelial cell antibodies predict graft function and allograft rejection in a low-risk kidney transplantation setting. Ann Lab Med. 2020;40:398&#x2013;408. doi: 10.3343/alm.2020.40.5.398.</Citation><ArticleIdList><ArticleId IdType="doi">10.3343/alm.2020.40.5.398</ArticleId><ArticleId IdType="pmc">PMC7169631</ArticleId><ArticleId IdType="pubmed">32311853</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou CC, Zhang Y, Irani RA, et al. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med. 2008;14:855&#x2013;862. doi: 10.1038/nm.1856.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1856</ArticleId><ArticleId IdType="pmc">PMC3267158</ArticleId><ArticleId IdType="pubmed">18660815</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>